Item 8.01 Other Events

As previously disclosed, on March 12, 2023, Pfizer Inc. ("Pfizer") entered into an Agreement and Plan of Merger with Seagen Inc. ("Seagen"), pursuant to which Pfizer will acquire Seagen through a merger (the "Merger"). The closing of the Merger is subject, among other things, to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). In addition, if Pfizer and Seagen refer the Merger to the European Commission (the "EC") for review under Article 4(5) of the EU Merger Regulation and the EC obtains jurisdiction to review the Merger as a result of such referral, receipt of approval from the EC for the Merger would become a condition for the closing of the Merger. On May 12, 2023, Pfizer and Seagen filed their respective notification and report forms pursuant to the HSR Act with the Antitrust Division of the United States Department of Justice and the Federal Trade Commission.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses